Key result
Early redo-sternotomy within 1 year shows no mortality difference versus reoperation at 1-5 years.
Why the study?
The optimal timing of reoperation for patients requiring repeat CABG and valve surgery was not well established.
Does early redo-sternotomy (<1 year) improve or worsen 1-year mortality and MACCE compared to intermediate (1-5 years) or late (>5 years) redo-sternotomy in patients requiring repeat CABG or valve surgery?
Cohort (n=1,748)
Yes
Does early redo-sternotomy (<1 year) improve or worsen 1-year mortality and MACCE compared to intermediate (1-5 years) or late (>5 years) redo-sternotomy in patients requiring repeat CABG or valve surgery?
Early redo-sternotomy (within 1 year) for CABG or valve surgery appears as safe as intermediate or late reoperations, with no significant increase in 1-year mortality or MACCE.
Answers are grounded in this paper and cite their sources.
Timing of redo-sternotomy shows no mortality or MACCE differences; leaves open optimal intervals for CABG/valve reoperations.
The optimal timing of reoperation for those who need repeat coronary artery bypass grafting (CABG) and valve surgery is not well established. Early re-entries may be technically challenging due to adhesions and incomplete healing, while delayed interventions may expose patients to progressive cardiac disease. Patients undergoing redo-sternotomy for CABG and valve surgery were identified from the TriNetX database and categorized into three cohorts based on the interval from their initial sternotomy: <1 year, 1–5 years, and > 5 years. Redo-sternotomies performed < 30 days after the initial procedure were excluded, as these typically represent early interventions for acute complications rather than planned reoperations. Two independent propensity score–matched analyses compared < 1 year vs. 1–5 years and 1–5 years vs. > 5 years, with separately matched 1–5 years cohorts for each comparison. Propensity score matching (PSM) was performed based on demographics, comorbidities, prior cardiac procedures, medications, and laboratory parameters including BMI. Primary outcomes included all-cause mortality, major adverse cardiovascular and cerebrovascular events (MACCE), and emergency department or hospital readmissions. Secondary outcomes included postoperative infection, atrial fibrillation, acute kidney injury, dialysis, cardiogenic shock, respiratory failure, and cerebrovascular events. After PSM in the < 1 year vs. 1–5 years analysis ( N = 305 in each group), redo-sternotomy within 1 year showed no significant differences in mortality, MACCE or readmissions. Combined cerebrovascular events were significantly reduced in the < 1 year group. In the 1–5 years vs. > 5 years analysis ( N = 439 in each group), outcomes were similar between groups, with no significant differences in mortality, MACCE, or readmissions. Atrial fibrillation was significantly higher in the 1–5 years group. All other secondary outcomes, including combined cerebrovascular events, were comparable. Redo-sternotomy within 1 year appears to be equally safe compared to later intervals, with comparable rates of adverse events, including mortality, MACCE, readmissions, postoperative infection, or AKI.
No takes yet. Share an insight, caveat, or question.
A 2026 study conducted a cohort in Redo-sternotomy for CABG or valvular surgery (n=1,748). Early redo-sternotomy (<1 year) vs. Intermediate redo-sternotomy (1-5 years) was evaluated on All-cause mortality at 1 year (HR 1.369, 95% CI 0.871-2.149, p=0.18). Early redo-sternotomy performed within 1 year of initial surgery showed no significant difference in 1-year all-cause mortality compared to reoperation at 1-5 years (14.4% vs 10.8%, HR 1.369, p=0.18).
Synapse has enriched 10 related papers. Consider them for comparative context: